ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19
COMPANY ANNOUNCEMENT - No. 26-2023 - 21 December 2023
BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, received notice of the following transactions by persons discharging managerial responsibilities according to MAR art. 19.
Under the EU’s Market Abuse Regulation art. 19, ViroGates A/S must notify the Danish Financial Supervisory Authority and publicly disclose transactions made by persons discharging managerial responsibilities and persons closely associated with them on trading ViroGates shares if the statutory threshold of 20,000 EUR limit is exceeded.
ViroGates hereby notifies and submits the following transactions of shares in ViroGates:
- Jakob Knudsen, Chief executive officer of ViroGates A/S, exercised subscription rights to shares and received 102,388 shares on 19 December 2023. The subscription for shares was related to the recently completed rights emission in ViroGates A/S.
- Lars Krogsgaard, Non-executive board member of ViroGates A/S, exercised subscription rights to shares and received 342,632 shares on 19 December 2023. The subscription for shares was related to the recently completed rights emission in ViroGates.
The notification forms related to the transactions are attached.
ViroGates further confirms that all pre-subscribers of shares, cf. company announcement no. 17-2023 from 9 November 2023, have subscribed and received the number of shares reported.
For further information, please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: jk@virogates.com
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: ca@vhcorp.se
About ViroGates
ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff as well as to monitor health in the general population.
The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
Disclosure regulation
Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.
Contacts
- Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com